117 related articles for article (PubMed ID: 36939068)
21. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
Samji H; Taha TE; Moore D; Burchell AN; Cescon A; Cooper C; Raboud JM; Klein MB; Loutfy MR; Machouf N; Tsoukas CM; Montaner JS; Hogg RS;
HIV Med; 2015 Feb; 16(2):76-87. PubMed ID: 25174373
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
[TBL] [Abstract][Full Text] [Related]
23. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.
Marcus JL; Leyden WA; Chao CR; Xu L; Quesenberry CP; Tien PC; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
AIDS Patient Care STDS; 2015 Jul; 29(7):370-8. PubMed ID: 26061798
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal analysis of immune reconstitution and metabolic changes in women living with HIV: A real-world observational study.
Wang X; Xiao J; Zhang L; Liu Y; Chen N; Deng M; Song C; Liu T; Zhang Y; Zhao H
Chin Med J (Engl); 2023 Sep; 136(18):2168-2177. PubMed ID: 37580056
[TBL] [Abstract][Full Text] [Related]
25. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
[TBL] [Abstract][Full Text] [Related]
26. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.
Ganesan A; Krantz EM; Huppler Hullsiek K; Riddle MS; Weintrob AC; Lalani T; Okulicz JF; Landrum M; Agan B; Whitman TJ; Ross MJ; Crum-Cianflone NF;
HIV Med; 2013 Feb; 14(2):65-76. PubMed ID: 22808988
[TBL] [Abstract][Full Text] [Related]
27. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial.
Baum MK; Campa A; Lai S; Sales Martinez S; Tsalaile L; Burns P; Farahani M; Li Y; van Widenfelt E; Page JB; Bussmann H; Fawzi WW; Moyo S; Makhema J; Thior I; Essex M; Marlink R
JAMA; 2013 Nov; 310(20):2154-63. PubMed ID: 24281460
[TBL] [Abstract][Full Text] [Related]
28. Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.
Bohlius J; Valeri F; Maskew M; Prozesky H; Garone D; Sengayi M; Fox MP; Davies MA; Egger M
Int J Cancer; 2014 Dec; 135(11):2644-52. PubMed ID: 24729433
[TBL] [Abstract][Full Text] [Related]
29. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with late presentation for HIV care in adolescents in Spain.
Epalza C; Domínguez-Rodríguez S; Cervantes E; Jiménez de Ory S; Frick MA; Fortuny C; Soler-Palacín P; Prieto-Tato L; Sainz T; Carreras-Abad C; Montero Alonso M; de Zárraga Fernández MA; Ocampo A; Rojo P; Navarro ML;
HIV Med; 2022 Dec; 23(11):1195-1201. PubMed ID: 36178091
[TBL] [Abstract][Full Text] [Related]
31. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
32. Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.
Blair JM; McNaghten AD; Frazier EL; Skarbinski J; Huang P; Heffelfinger JD
MMWR Surveill Summ; 2011 Sep; 60(11):1-20. PubMed ID: 21881551
[TBL] [Abstract][Full Text] [Related]
33. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
34. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
35. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
36. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
Harboe ZB; Larsen MV; Ladelund S; Kronborg G; Konradsen HB; Gerstoft J; Larsen CS; Pedersen C; Pedersen G; Obel N; Benfield T
Clin Infect Dis; 2014 Oct; 59(8):1168-76. PubMed ID: 25038114
[TBL] [Abstract][Full Text] [Related]
37. Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second-line antiretroviral therapy in central China: A retrospective cohort study.
Zhu K; Xu Q; Ma Y; Li P; Jia H; Jiang Q; Wang Y; Wu Z; Wang D; Guo H; Jin Y
J Med Virol; 2022 Oct; 94(10):4975-4982. PubMed ID: 35710693
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.
Guy R; Wand H; McManus H; Vonthanak S; Woolley I; Honda M; Read T; Sirisanthana T; Zhou J; Carr A;
AIDS Patient Care STDS; 2013 Dec; 27(12):681-91. PubMed ID: 24320013
[TBL] [Abstract][Full Text] [Related]
39. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy.
Soriano-Sarabia N; Abad MA; Vallejo A; Gutiérrez S; Leal M
Clin Microbiol Infect; 2006 Mar; 12(3):290-3. PubMed ID: 16451419
[TBL] [Abstract][Full Text] [Related]
40. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
